482-53-1
基本信息
CID 95168
NSC 21565
OSAJIN(RG)
Osajin >=95% (LC/MS-ELSD)
5-hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6-(3-methylbut-2-enyl)pyrano[2,3-h]chromen-4-one
5-hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6-(3-methyl-2-butenyl)-4H,8H-pyrano[2,3-f]chromen-4-one
5-Hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6-(3-methyl-2-butenyl)-4H,8H-benzo[1,2-b:3,4-b']dipyran-4-one
4H,8H-Benzo[1,2-b:3,4-b']dipyran-4-one,5-hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6-(3-methyl-2-buten-1-yl)-
物理化學(xué)性質(zhì)
常見問題列表
Apoptosis
Osajin significantly decreases the viability of human NPC cells (TW076, CG1 and TW04 cells) in a dose-dependent manner. Osajin induces apoptosis in human NPC cells through multiple apoptotic pathways, including the extrinsic death receptor pathway, and intrinsic pathways relying on mitochondria and endoplasmic reticulum stress. Osajin exhibits growth inhibitory activity on six human cancer cell lines, including kidney, lung, prostate, breast, melanoma and colon cancer cells.
Osajin and pomiferin attenuates the myocardial dysfunction provoked by ischemia reperfusion. This is confirmed by an increase in both antioxidant enzyme values and total antioxidant activity. The cardioprotection provided by osajin and pomiferin treatment results from the suppression of oxidative stress and this correlates with improved ventricular function.